Literature DB >> 18636228

Anticoagulation: where we are and where we need to go.

Geoffrey D Barnes1, James B Froehlich.   

Abstract

Although a commonly prescribed medication, warfarin has unique pharmacologic properties that make dosing challenging for many primary care physicians. When a patient's international normalized ratio (INR) is out of the therapeutic range, they are at increased risk for thrombotic or hemorrhagic complications. We have reviewed the current literature for quality improvement techniques to minimize adverse outcomes and improve anticoagulation care. The use of anticoagulation clinics, computer-guided dosing and patient self-monitoring have been demonstrated to reduce adverse events or improve patient and provider satisfaction. Additional techniques, including genetic-based dosing, concurrent vitamin K administration and development of risk-assessment tools, have been discussed, but not fully developed or assessed in the literature. We identify tools that can be implemented today as well as those currently under development for the improvement in anticoagulation care.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18636228     DOI: 10.1007/s11239-008-0256-4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  26 in total

Review 1.  Managing oral anticoagulant therapy.

Authors:  J Ansell; J Hirsh; J Dalen; H Bussey; D Anderson; L Poller; A Jacobson; D Deykin; D Matchar
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Reducing risks for patients receiving warfarin.

Authors:  Jennifer Bush
Journal:  Fam Pract Manag       Date:  2002 Jul-Aug

3.  Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation.

Authors:  L Poller; C R Shiach; P K MacCallum; A M Johansen; A M Münster; A Magalhães; J Jespersen
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

4.  Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: A cost-effectiveness analysis.

Authors:  J E Lafata; S A Martin; S Kaatz; R E Ward
Journal:  J Thromb Thrombolysis       Date:  2000-06       Impact factor: 2.300

5.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

6.  Patient and physician satisfaction with a telephone-based anticoagulation service.

Authors:  A D Waterman; G Banet; P E Milligan; A Frazier; E Verzino; B Walton; B F Gage
Journal:  J Gen Intern Med       Date:  2001-07       Impact factor: 5.128

7.  Cost-effectiveness of self-managed anticoagulant therapy in Germany.

Authors:  U Taborski; F J Wittstamm; A Bernardo
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

8.  Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs.

Authors:  E Chiquette; M G Amato; H I Bussey
Journal:  Arch Intern Med       Date:  1998 Aug 10-24

Review 9.  The future of anticoagulation clinics.

Authors:  B Gail Macik
Journal:  J Thromb Thrombolysis       Date:  2003 Aug-Oct       Impact factor: 2.300

Review 10.  Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.

Authors:  Brian F Gage; Lawrence J Lesko
Journal:  J Thromb Thrombolysis       Date:  2007-10-01       Impact factor: 2.300

View more
  1 in total

1.  Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.

Authors:  Arne Lauer; Flor A Cianchetti; Elizabeth M Van Cott; Frieder Schlunk; Elena Schulz; Waltraud Pfeilschifter; Helmuth Steinmetz; Chris B Schaffer; Eng H Lo; Christian Foerch
Journal:  Circulation       Date:  2011-09-12       Impact factor: 29.690

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.